41332-24-5
41332-24-5 結(jié)構(gòu)式
基本信息
1-【4-(二苯甲基)-1-哌嗪基】-3,3-二苯基-1-丙酮
1-[4-(二苯基甲基)-1-哌嗪]-3,3-二苯基-1-丙酮
39-1B4
CS-2371
NP 118809
NP118809 (39-1B4
39-1B4
NP-118809
NP 118809
NP118809
1-(DiphenylMethyl)-4-(1-oxo-3,3-diphenylpropyl)piperazine
Piperazine, 1-(diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)-
1-[4-(DiphenylMethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone
物理化學(xué)性質(zhì)
制備方法
606-83-7
841-77-0
41332-24-5
1-(Diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)piperazine的合成步驟：向1-(Diphenylmethyl)piperazine（2.08 mmol）的無水二氯甲烷（40 mL）溶液中，在氮?dú)獗Ｗo(hù)下加入3,3-diphenylpropionic acid（0.472 g，2.08 mmol）。隨后向反應(yīng)混合物中加入EDC（0.797 g，4.16 mmol）和催化量的DMAP，反應(yīng)混合物在室溫下氮?dú)夥諊袛嚢柽^夜。反應(yīng)完成后，將混合物減壓濃縮。將殘余物溶解于乙酸乙酯與水的混合溶劑（10:1，150 mL）中。有機(jī)相依次用水（30 mL，2次）和10% NaOH溶液（30 mL）洗滌，用無水硫酸鎂干燥后，減壓蒸發(fā)除去溶劑。所得粗產(chǎn)物通過柱色譜法純化，洗脫劑為石油醚與乙酸乙酯的混合溶劑（3:1），最終得到目標(biāo)產(chǎn)物1-(diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)piperazine，產(chǎn)率為78%。
參考文獻(xiàn)：
[1] Patent: US2004/259866, 2004, A1
[2] Patent: US6951862, 2005, B2
[3] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 22, p. 6467 - 6472
[4] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 4, p. 1378 - 1383
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | HY-14462 | 1-【4-(二苯甲基)-1-哌嗪基】-3,3-二苯基-1-丙酮 NP118809 | 41332-24-5 | 100mg | 744元 |
| 2025/05/22 | HY-14462 | 1-【4-(二苯甲基)-1-哌嗪基】-3,3-二苯基-1-丙酮 NP118809 | 41332-24-5 | 10mM * 1mLin DMSO | 818元 |
| 2025/05/22 | HY-14462 | 1-【4-(二苯甲基)-1-哌嗪基】-3,3-二苯基-1-丙酮 NP118809 | 41332-24-5 | 200mg | 930元 |
常見問題列表
|
N-Type Ca 2+ Channel 0.11 μM (IC 50 ) |
L-type calcium channel 12.2 μM (IC 50 ) |
NP118809 is a potent N-type calcium channel blocker, with an IC 50 of 0.11 μM; also inhibits L-type calcium channel with an IC 50 of 12.2 μM. NP118809 inhibits the hERG potassium channel in HEK cells, with an IC 50 of 7.4 μM.
NP118809 (25 mg/kg, i.p.) shows significant analgesic activity in the phase IIA portions of the rat formalin model. NP118809 (30 mg/kg, p.o.) results in 80.3% inhibition of mechanical allodynia and 96.3% inhibition of thermal hyperalgesia in the rat spinal nerve ligation model.